Drug intelligence / Profile preview

corticosteroids + immunoglobulin + romiplostim

Development stage
Unknown
Lead developer
Amgen
Modality
Recombinant Proteins and Enzymes, Small Molecules
Administration
Oral, Intravenous, Subcutaneous
01

Overview

This is a combination therapy consisting of corticosteroids, immunoglobulin (typically intravenous immunoglobulin, IVIG), and romiplostim. It is used primarily in the management of immune thrombocytopenia (ITP), especially in cases that are refractory to standard treatments. - **Corticosteroids** act as immunosuppressants, reducing platelet destruction by dampening the immune response. - **Immunoglobulins** (IVIG) provide passive immunity and modulate immune activity to decrease platelet clearance. - **Romiplostim** is a thrombopoietin receptor agonist that stimulates megakaryocytes in the bone marrow to increase platelet production by activating the thrombopoietin receptor (c-Mpl). The combination aims to both reduce destruction and enhance production of platelets, offering synergistic efficacy for patients with chronic or refractory ITP[1][3][4].

02

Targets

TPOR (Thrombopoietin receptor)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on corticosteroids + immunoglobulin + romiplostim.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on corticosteroids + immunoglobulin + romiplostim.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call